Pay in 4 interest-free payments of $6.02 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Limitations This is a single case with multiple compounding factors: NSAIDs, heavy alcohol use, and an unsupervised dose escalation
When we use QALYs, the VBP becomes $10,817, implying that the larger weight reduction and more inclusive accounting of obesity-related health impacts together add about 12% to the estimate of value, compared to ICER
Dhir G, Cusi K (2018) Glucagon like peptide-1 receptor agonists for the management of obesity and nonalcoholic fatty liver disease: a novel therapeutic option
lucidum spores (GLSP) at a dose of 1 g/day supplemented orally for 4 weeks were used in adult male Sprague-Dawley rats
No human clinical trials have been conducted
What do the incretins do
US$ 27.47
US$ 21.94
US$ 21.83
US$ 24.35
US$ 25.80
US$ 20.95
